Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Sep;27(1-3):149-64.
doi: 10.1023/A:1008008719699.

Topoisomerase I inhibitors and drug resistance

R E Parchment  1 , A Pessina
Affiliations

Topoisomerase I inhibitors and drug resistance

R E Parchment et al. Cytotechnology. 1998 Sep.

Abstract

DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing the phenomenon. This article describes the role of topoisomerase I in cell functions and the methods used to assess its in vitro catalytic activity. It reviews the mechanisms of cytotoxicity of the most specific antitopoisomerase I drugs by considering also the phenomenon of drug resistance. Some factors useful to drive the future perspectives in the development of new topoisomerase I inhibitors are also evidenced and discussed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 1996;7:166–74. - PubMed
    1. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kuzunoki Y, Takemoto Y, Okada K. Characterization of a mammalian mutant with camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA. 1987;84:5565–69. - PMC - PubMed
    1. Andrews BJ. Gene expression-dialogue with the cell cycle. Nature. 1992;355:393–4. - PubMed
    1. Baguley BC, Holdway KM, Fray LM. Design of DNAintercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst. 1990;82:398–402. - PubMed
    1. Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry. 1995;19:134–45. - PubMed